There is a genuine connection between NAD⁺ and glutathione, and it is not the one the drip menu implies. NADPH — the phosphorylated, reduced relative of NAD⁺ — is the molecule that powers glutathione reductase, the enzyme that converts spent glutathione back into its active form. No NADPH, no recycling.
What does not follow is that buying NAD⁺ raises your glutathione, or that the two belong in the same bag. No published trial has tested the combination in people, and each one’s own evidence base stops well short of what a clinic’s upsell implies.
The mechanism, stated precisely
Glutathione works by being oxidized. It donates electrons to neutralize a reactive species and becomes GSSG — the oxidized dimer — which is useless until something puts the electrons back. Glutathione reductase does that, and it takes its electrons from NADPH.
NADPH comes from NADP⁺, and NADP⁺ is made from NAD⁺ by an enzyme called NAD kinase. So there is a real chain: NAD⁺ → NADP⁺ → NADPH → regenerated glutathione. It is why a cell short of NAD⁺ would eventually be a cell short of antioxidant capacity, and it is the honest version of the argument clinics gesture at.
Notice how many steps that is, and note that none of them has been shown to be the limiting one in a healthy person. A chain that exists is not a chain that is short of links. This is the recurring pattern in this category — a plausible mechanism presented as a demonstrated result — and it is the same reasoning error we unpack in what the benefits evidence shows.
What glutathione supplementation has actually shown
More than most people assume, and less than the price of an infusion implies. A six-month randomized, double-blinded, placebo-controlled trial gave oral glutathione at 250 or 1,000 mg a day to 54 non-smoking adults (n = 54). At six months, mean glutathione levels in the high-dose group rose 30–35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells (P < 0.05); natural killer cell cytotoxicity increased more than two-fold against placebo at three months (P < 0.05). Levels returned to baseline after a one-month washout [1].
That is the same shape as the NAD⁺ literature: a body-stores endpoint that moves convincingly, an immune marker that moves, and a return to baseline when you stop. What it does not contain is a clinical outcome anyone is selling — and it was oral, not intravenous.
The combination has not been tested
We searched rather than assumed. In September 2026, PubMed returned zero records for (NAD+[Title] OR “nicotinamide adenine dinucleotide”[Title]) AND glutathione[Title] AND randomized controlled trial[Publication Type]. Broadening to any human study mentioning both alongside infusion or intravenous administration returned six records, none of which tested the pairing: a review of intravenous longevity therapy, two animal or cell studies, a glutathione-only infusion trial in angioplasty patients, and two unrelated papers.
That review is worth quoting directly, because it covers exactly the product being sold. Assessing intravenous administration of high-dose vitamins, minerals, amino acids, coenzyme Q10, alpha-lipoic acid, glutathione and NAD⁺ as a longevity therapy, it found the evidence drawn largely from preclinical models and small clinical series, with placebo-controlled trials scarce and underpowered or conflicting, and concluded that the practice should be regarded as experimental rather than evidence-based until adequately powered randomized trials exist [2].
Why they are sold together anyway
Because a drip bag holds more than one thing, and each addition carries a margin. The two also share a story — cellular protection, oxidative stress, aging — that lets a menu present them as complementary without anyone having to show they are.
The practical effect is on your ability to judge value. An infusion priced as a bundle cannot be compared with one priced per component, and neither can be compared with anything at all if the milligram figures are missing — which, on the IV therapy board, they usually are. Among the sellers we can verify, The IV Doc is the only IV provider publishing a dose: $799 for a stated 250 mg, about $3.20 a milligram, against roughly $0.15–$0.25 for injections that publish one.
There is a cheaper adjacent question too. N-acetylcysteine is the precursor most often used to raise glutathione, and it is an oral product costing a fraction of a drip — how NAD⁺ and NAC compare is the page for that.
What to ask if this is on the menu in front of you
How many milligrams of each, and what the price would be for the NAD⁺ alone. Whether there is any trial of the combination — there is not, but the answer you get is informative. And what the total cost of the protocol is, not the single session, which is the number our annual cost tool is built to recover.
The biochemistry linking these two molecules is real and rather elegant. It is not, on any published evidence, a reason to buy them in the same bag.